Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04844463 · ClinicalTrials.gov registry record · Phase 1

A Study of JNJ-68179280 in Healthy Participants

A Phase 1 study of Healthy, sponsored by Janssen Research & Development.

Completed
Registry status
Phase 1
Development phase
94
Enrollment target
1
Study location

NCT04844463 is a Phase 1 study of Healthy that has completed, run by Janssen Research & Development. The registered enrollment target is 94 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04844463, a Phase 1 study of Healthy, has completed, sponsored by Janssen Research & Development.

COMPLETED
Registry status
Phase 1
Development phase
94 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the safety and tolerability of JNJ-68179280 compared with placebo after administration of single ascending oral doses of JNJ-68179280 administered to healthy participants (Part 1), multiple ascending oral doses of JNJ-68179280, administered to healthy participants once daily (Cohorts 1 through 4) or twice daily (Cohort 5) over 14 consecutive days (Part 2) and multiple ascending oral doses of an alternative JNJ-68179280 formulation, administered to healthy participants once daily over 14 consecutive days (Part 3 if conducted).

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG JNJ-68179280

Study Locations (1)

Nebraska

  • Celerion - Lincoln

Trial Details

FieldValue
Enrollment Target 94 participants
Start Date 2021-05-26
Est. Completion 2023-03-13
Phase Phase 1

Sponsor

Janssen Research & Development

593 total trials

What the Registry Record Tells You About NCT04844463

The ClinicalTrials.gov registry entry for NCT04844463 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (85% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04844463 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.

Frequently Asked Questions

What is clinical trial NCT04844463 about?

NCT04844463 is a clinical study titled "A Study of JNJ-68179280 in Healthy Participants". The purpose of this study is to evaluate the safety and tolerability of JNJ-68179280 compared with placebo after administration of single ascending oral doses of JNJ-68179280 administered to healthy participants (Part 1), multiple ascending oral doses of JNJ-68179280, administered to healthy partici...

What is the current status of trial NCT04844463?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2021-05-26. Estimated completion is 2023-03-13.

What conditions does trial NCT04844463 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT04844463?

The interventions under investigation include: Placebo (OTHER), JNJ-68179280 (DRUG).

Who is sponsoring clinical trial NCT04844463?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04844463 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.